Urology Department, Imam Reza University Hospital, Tabriz, Iran.
Int J Gen Med. 2011 Jan 11;4:35-9. doi: 10.2147/IJGM.S16063.
To compare the effects of tamsulosin and prazosin on clinical and urodynamic parameters in women with voiding dysfunction.
Forty women aged 20-65 years with a clinical diagnosis of voiding dysfunction were blindly randomized to two equal groups for treatment with tamsulosin 0.4 mg or 1-2 mg of prazosin daily. Symptom assessment with the American Urological Association Symptom Score (AUASS) and urodynamic evaluation was performed initially and after three months of treatment. Patient satisfaction was evaluated and severe adverse drug effects recorded. Statistical analysis was carried out using the Student's t-test and Mann-Whitney U test.
Although AUASS improved in both groups, the rate of improvement was larger in the tamsulosin group. Urodynamic parameters improved but did not normalize in both groups. Adverse side effects from medication in the prazosin group were more common than in the tamsulosin group. Most of the patients in the tamsulosin group (80%) were satisfied with their treatment compared with those in the prazosin group (45%).
Tamsulosin and prazosin are both effective in palliating symptoms of women with voiding dysfunction and improving their urodynamic parameters. Tamsulosin may be the preferred drug to prescribe because of its more amenable side effect profile and greater patient satisfaction.
比较坦索罗辛和哌唑嗪对排尿功能障碍女性的临床和尿动力学参数的影响。
40 名年龄在 20-65 岁之间、有排尿功能障碍临床诊断的女性患者被盲目随机分为两组，分别接受坦索罗辛 0.4mg 或 1-2mg 每日治疗。最初和治疗三个月后进行美国泌尿协会症状评分（AUASS）和尿动力学评估。评估患者满意度并记录严重药物不良反应。使用学生 t 检验和曼-惠特尼 U 检验进行统计分析。
尽管两组的 AUASS 均有所改善，但坦索罗辛组的改善率更大。两组的尿动力学参数均有所改善但未恢复正常。哌唑嗪组的药物不良反应比坦索罗辛组更常见。坦索罗辛组的大多数患者（80%）对其治疗满意，而哌唑嗪组的患者（45%）则不然。
坦索罗辛和哌唑嗪均能有效缓解排尿功能障碍女性的症状并改善其尿动力学参数。由于坦索罗辛的副作用谱更易于处理且患者满意度更高，因此可能是首选药物。
